Pacira Contract

what you have here ,,,,is a failuuuuure to communicate



From the prison guard to Paul Newman

 

there is no failure to communicate....there is a culture of lying. lied when they hired the salesforce, lied about the product availability, lied about the 1st quarter bonus, lied about the J code, lied about compensation again and again ---and just listen to those investor calls.

 

Reduce expenses/debt, improve the books to make the company attractive to a buyer, sell at a good price, Stack cashes in his stock options, and walk. This is not a long term company. We all knew this going in.

 

IF they don't destroy the product and the company ..........before they can sell it

 

Very bad comp plan....people will start moving on just when you need the best.

What are you thinking PaulC. You have bad performers reaching the 40 dol threshold early and screwing your top people...not good,!

 

"bad performers"? get over yourself. go do some work..its called growing your business

 

This is a top performer Asswipe!

 

its a company full of unqualified hacks who knew or sucked up to the right person--stack. they are an FDA and SEC sitting duck --if anyone ever takes a good look at the widespread promotion for tap block and other uses for which there is no data or indication it could be ugly --or leaking early data results ....

 

people "will start moving on"????? REALLY? Almost my entire district is GONE!! I think we are all looking, especially based on how they've treated us since being brought over to Pacira.

 

Pretty simple, they only need us to get surgeons to use it. Once it becomes habit, you become expendable.

 

No matter what anyone at corporate says, this one product company could be sold at any point. DW a national sales manager? He's a pharmacist with no sales experience. Have to question who made that decision. There will be a mass exodus from this lack-of-management company which devalues its' sales force.

 

Pacira is for sale to the bidder with the right price-it is not a viable company with one product that costs so much to manufacture, ship and sell; exparel is competing in a market with many generic (i.e cost effective) and effective alternatives, it is a niche product that primarily belongs in the ambulatory setting or short stay surgery and can only truly expand in a significant way when and IF it gets the nerve block indication. Even that indication is no guarantee-you cannot turn exparel off. it has risks. you can remove a pain ball if there are problems, you can turn off the epidural. once exparel is injected it is there for 96 hours..........that is not necessarily something everybody views as a good thing.

 

DW national sales manager. Enough said.

 

and homer

 

Its like the people here just sit there and spank the monkey,,,im just sayen,,

everyone is all over the place and spinning wheels,,,lets get it together folks

drop your thing and start doing the things that will move this drug...

 

Name Number of Shares of Common Stock Underlying Option
David Stack 350,000
James Scibetta 150,000
Taunia Markvicka 150,000
John Pratt 150,000
Gary Patou, M.D. 40,000
Lauren Riker 30,000

 

Think the stock is way overvalued. Wonder how that happens when other hire performing companies have to try so much harder to keep prices up.

 

Not to mention all the off-label usage of this stuff by orthopods-----it will be fun to sit back and watch all the lawsuits roll in when Exp gets into a few joints.........

 

off label is much of the use...........and they are promoting nerve block like crazy.

 

Pacira Pharmaceuticals, Inc.
Compensation for 2011
Salary $409,046
Bonus $206,000
All other compensation $1,504
Total Compensation $616,550
Options Exercised for 2011
Number of securities underlying options exercisable 151,095
Number of securities underlying options unexercisable 34,865
Stock Ownership for 2011
Number of shares owned 20,600